193 results on '"Yuda, Junichiro"'
Search Results
2. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
3. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
4. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
5. Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment
6. Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
7. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
8. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
9. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
10. Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients
11. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma
12. MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
13. O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
14. P38-8 Phase 1/2 study of menin inhibitor DSP-5336 in acute leukemia with and without MLL rearrangement or NPM1 mutation
15. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
16. MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)
17. POSTER: MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)
18. P1031: PRELIMINARY DATA FROM THE PHASE 1/2 STUDY OF TP-3654, AN INVESTIGATIONAL SELECTIVE PIM1 KINASE INHIBITOR, SHOWED CYTOKINE REDUCTION AND CLINICAL RESPONSES IN RELAPSED/REFRACTORY MYELOFIBROSIS
19. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence
20. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
21. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
22. A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
23. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors
24. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
25. MO10-2 Emerging molecular targets in AML: IDH1/2- and menin-related mutations (HM-SCREEN-JAPAN01)
26. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
27. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
28. Abstract 5185: First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination
29. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
30. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
31. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia
32. Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis
33. Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01
34. Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01
35. Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
36. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
37. A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies
38. Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.
39. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long‑term remission
40. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
41. Emerging Immunotherapy for Acute Myeloid Leukemia
42. STAMP inhibitor Asciminib and medium-chain fatty-acid derivative AIC-47: novel therapies for chronic myeloid leukemia
43. AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma
44. The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
45. Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL Ins35bp variant via inhibition of RNA polymerase II on genomic BCR‐ABL
46. Multidisciplinary team Management System for Adverse Events Occurring in New Cancer Immunotherapies
47. CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target
48. Tyrosine kinase inhibitors induce alternative spliced BCR‐ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR‐ABL.
49. O2-4-1 - Multidisciplinary team Management System for Adverse Events Occurring in New Cancer Immunotherapies
50. Persistent detection of alternatively splicedBCR ‐ ABLvariant results in a failure to achieve deep molecular response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.